Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.77 USD | -4.22% | -11.56% | +59.40% |
Financials (USD)
Sales 2024 * | 604K | Sales 2025 * | 8.03M | Capitalization | 238M |
---|---|---|---|---|---|
Net income 2024 * | -99M | Net income 2025 * | -93M | EV / Sales 2024 * | 395 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 29.7 x |
P/E ratio 2024 * |
-2.65
x | P/E ratio 2025 * |
-3.38
x | Employees | 122 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.78% |
Latest transcript on Inovio Pharmaceuticals, Inc.
1 day | -7.86% | ||
1 week | -13.27% | ||
Current month | -26.51% | ||
1 month | -4.85% | ||
3 months | +18.06% | ||
6 months | +83.51% | ||
Current year | +66.67% |
Managers | Title | Age | Since |
---|---|---|---|
Jacqueline Shea
CEO | Chief Executive Officer | 58 | 19-03-24 |
Peter Kies
DFI | Director of Finance/CFO | 60 | 02-05-31 |
Chief Tech/Sci/R&D Officer | - | 07-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Simon Benito
CHM | Chairman | 79 | 03-11-30 |
Lota Zoth
BRD | Director/Board Member | 64 | 17-12-31 |
Jay Shepard
BRD | Director/Board Member | 66 | 20-01-14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 9.755 | -4.36% | 201 498 |
24-04-18 | 10.2 | -7.86% | 401,381 |
24-04-17 | 11.07 | +14.89% | 706,286 |
24-04-16 | 9.635 | -12.33% | 747,681 |
24-04-15 | 10.99 | -0.36% | 284,812 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+66.67% | 238M | |
-1.82% | 41.35B | |
+42.21% | 40.38B | |
+2.56% | 39.05B | |
-12.11% | 26.67B | |
+3.09% | 24.07B | |
-24.16% | 18.36B | |
+22.12% | 11.6B | |
-3.74% | 11.68B | |
+7.75% | 11.15B |
- Stock Market
- Equities
- INO Stock